LON:OPTI

OptiBiotix Health Interim Earnings Results & Report

OptiBiotix Health logo
GBX 4.40 -0.15 (-3.30%)
As of 11:57 AM Eastern

OptiBiotix Health reported Interim earnings on September 16, 2025. The company reported EPS of -GBX 1.15.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

OptiBiotix Health EPS Results

Actual EPS
-GBX 1.15
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OptiBiotix Health Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

OptiBiotix Health Interim Earnings FAQ

OptiBiotix Health (LON:OPTI) reported earnings of -GBX 1.15 per share for Interim. The report was announced on Tuesday, September 16, 2025.

OptiBiotix Health Earnings Headlines

OptiBiotix Health Plc H1 Loss Rises
Intel Shares Jumped 177% After Elon Musk's Deal
Elon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the analyst who flagged Nvidia in 2016 before its 37,800% run, says Musk may announce a new AI partnership any day.tc pixel
See More OptiBiotix Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OptiBiotix Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OptiBiotix Health and other key companies, straight to your email.

About OptiBiotix Health

OptiBiotix Health (LON:OPTI) (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks. OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

View OptiBiotix Health Profile